GeislerJ., HaynesB., AnkerG.: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.J Clin Oncol,20: 751–757, 2002.
2.
ThijssenJ.H., BlankensteinM.A.: Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues.Eur J Cancer Clin Oncol,25: 1953–1959, 1989.
3.
MillerW.R., O'NeillJ.: The importance of local synthesis of estrogen within the breast.Steroids,50: 537–548, 1987.
4.
JordanV.C.: Is tamoxifen the Rosetta stone for breast cancer?J Natl Cancer Inst,95: 338–340, 2003.
5.
GershanovichM., ChaudriH.A., CamposD.: Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer.Ann Oncol,9: 639–645, 1998.
6.
MouridsenH., GershanovichM., SunY.: Phase III study of letrozole versus tamoxifen as first line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from international letrozole breast cancer group.J Clin Oncol,21: 2101–2109, 2003.
7.
Early Breast Cancer Trialists Collaborative Group:Tamoxifen for early breast cancer: an overview of the randomised trials.Lancet,351: 1451–1467, 1998.
8.
SmithI.E., DowsettM.: Aromatase inhibitors in breast cancer.N Engl J Med,348: 2431–2442, 2003.
9.
GossP., IngleJ., MartinoS.: A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer.N Engl J Med,349: 1793–1802, 2003.
